**Background of FPR2 Antibody**
The formyl peptide receptor 2 (FPR2), a member of the G protein-coupled receptor (GPCR) family, plays a critical role in immune regulation and inflammatory responses. Initially identified as a receptor for bacterial-derived formylated peptides, FPR2 also binds diverse endogenous ligands, including annexin A1. lipoxin A4. and amyloid-beta, enabling its involvement in both pro-resolving and pro-inflammatory pathways. This functional duality makes FPR2 a key mediator in balancing immune homeostasis, with implications in chronic inflammation, infection, and tissue repair.
FPR2 is expressed on immune cells (e.g., neutrophils, macrophages) and non-immune cells (e.g., endothelial cells), influencing processes like chemotaxis, phagocytosis, and cytokine release. Dysregulation of FPR2 signaling is linked to diseases such as atherosclerosis, Alzheimer’s disease, and cancer, highlighting its therapeutic potential.
FPR2 antibodies are essential tools for studying receptor localization, expression levels, and signaling mechanisms. They enable targeted inhibition or activation of FPR2 in experimental models, aiding in the exploration of its pathophysiological roles. Recent research focuses on developing FPR2-targeted therapies, including monoclonal antibodies, to modulate inflammatory diseases or enhance microbial clearance. However, challenges remain in understanding ligand-specific signaling bias and receptor cross-talk. Overall, FPR2 antibodies serve as vital reagents for unraveling the receptor's complex biology and advancing translational applications.